checkAd

     202  0 Kommentare Helix Announces Initiation of First Clinical Site for US Study - Seite 3

    Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.

    Investor Relations:
    Helix BioPharma Corp.
    Tel: (905) 841-2300
    Email: ir@helixbiopharma.com


    Seite 3 von 3

    Verfasst von Marketwired
    Helix Announces Initiation of First Clinical Site for US Study - Seite 3 AURORA, ON--(Marketwired - Dec 22, 2014) -  Helix BioPharma (TSX: HBP) (FRANKFURT: HBP) announced today that its United States Phase I study of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV …

    Schreibe Deinen Kommentar

    Disclaimer